Introduction: Statins are one of the most widely used therapies in different groups of patients not only
because of cholesterol-lowering properties but also due to their non-lipid related mechanisms. However,
the effects of atorvastatin on inflammatory and coagulation markers in type 2 diabetic patients are not well
Objectives: To evaluate, the effects of two different doses of atorvastatin on lipid profile, inflammatory
coagulation markers, and liver enzymes in type 2 diabetic patients.
Patients and Methods: In a randomized double-blinded controlled trial, 150 diabetic patients were
randomly assigned to get atorvastatin 10 mg/d (n = 74) or 40 mg/d (n = 76) for 12 weeks. The concentration
of biomarkers was determined both at the onset of the study as well as at the completing time of the
Results: Significant differences between the mean levels of lipid profiles, fibrinogen, interleukin-1 (IL-1)
and IL-6 were observed between two groups after three months treatment with atorvastatin 10 and 40 mg/d
(P<0.05). Furthermore, significant improvement in all blood values after atorvastatin 40 mg/d ingestion was
observed (P<0.05) except for homocysteine and creatine phosphokinase (CPK) levels (P>0.05).
Conclusion: Atorvastatin therapy especially with higher dose was associated with inflammation and
coagulation parameters improvement in diabetic individuals.